IMR Press / FBE / Volume 7 / Issue 1 / DOI: 10.2741/E717

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
HPV and CSC in HNSCC cisplatin resistance
Show Less
1 SIU School of Medicine, Springfield, IL, 62702, USA

*Author to whom correspondence should be addressed.

Front. Biosci. (Elite Ed) 2015, 7(1), 66–76; https://doi.org/10.2741/E717
Published: 1 January 2015
Abstract

Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is offered by a distinct disease entity in HNSCC – HPV+ OPSCC. It responds far more favorably to cisplatin than non-HPV driven HNSCC. Another intriguing aspect of head and neck cancer biology is the emergence of the CD44+ cancer stem cell - the tumor initiating population that in all likelihood is the root cause of therapeutic resistance. The critical question is, are there any differences between the CD44+ CSC population of an HPV+ OPSCC and a non-HPV HNSCC? In this regard, the inverse relation between EGFR levels and HPV status in OPSCC may be a common thread that connects the better response rates of HPV+ OPSCC with the contribution of CD44+ stem cells of HNSCC to chemoresistance.

Keywords
HNSCC
Head And Neck Cancer
Cancer stem cells
Cisplatin
HPV
EGFR
CD44
Review
Share
Back to top